J H Gurwitz
Overview
Explore the profile of J H Gurwitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
2908
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bohn R, Glynn R, Gurwitz J, Everitt D, Gilden D, Avorn J
J Glaucoma
. 2009 Nov;
3(3):259-64.
PMID: 19920606
No abstract available.
2.
Avorn J, Glynn R, Gurwitz J, Bohn R, Monane M, Everitt D, et al.
J Glaucoma
. 2009 Nov;
2(3):158-65.
PMID: 19920512
We conducted a case-control study to measure the risk of pulmonary side effects following the use of topical glaucoma medications, particularly the beta blockers, and to identify patients at highest...
3.
Platt R, Davis R, Finkelstein J, Go A, Gurwitz J, Roblin D, et al.
Pharmacoepidemiol Drug Saf
. 2002 Jan;
10(5):373-7.
PMID: 11802579
Research and education programs in therapeutics that combine the data, organizational capabilities, and expertise of several managed care organizations working in concert can serve an important role when a single...
4.
McCormick D, Gurwitz J, Goldberg R, Becker R, Tate J, Elwell A, et al.
Arch Intern Med
. 2001 Dec;
161(20):2458-63.
PMID: 11700158
Background: Evidence-based clinical practice guidelines recommend the use of warfarin sodium for stroke prevention in most patients with atrial fibrillation (AF) who do not have risk factors for hemorrhagic complications,...
5.
Gurwitz J, Guadagnoli E, Landrum M, Silliman R, Wolf R, Weeks J
Med Care
. 2001 Nov;
39(12):1339-44.
PMID: 11717575
Background: Institutional Review Boards vary in regard to the conditions imposed on investigators concerning contacting potential subjects to participate in health-services research studies. Objective: The impact of more active involvement...
6.
Field T, Gurwitz J, Avorn J, McCormick D, Jain S, Eckler M, et al.
Arch Intern Med
. 2001 Jul;
161(13):1629-34.
PMID: 11434795
Background: In a prospective study of nursing home residents, we found adverse drug events (ADEs) to be common, serious, and often preventable. To direct prevention efforts at high-risk residents, information...
7.
Majumdar S, Inui T, Gurwitz J, Gillman M, McLaughlin T, Soumerai S
J Gen Intern Med
. 2001 Jun;
16(6):351-9.
PMID: 11422631
Objective: Recent reports have linked calcium channel blockers (CCBs) with an increased risk of acute myocardial infarction (AMI). We sought to determine to what extent physicians relinquished CCBs following these...
8.
Yood R, Harrold L, Fish L, Cernieux J, Emani S, Conboy E, et al.
Arch Intern Med
. 2001 Jun;
161(10):1322-7.
PMID: 11371261
Background: Treatment with glucocorticoids is the leading cause of drug-induced osteoporosis. Currently available guidelines indicate that patients receiving long-term glucocorticoid therapy should receive measures to prevent osteoporosis. Objectives: To examine...
9.
Baldor R, Field T, Gurwitz J
Acad Med
. 2001 May;
76(5):510-1.
PMID: 11346546
No abstract available.
10.
Angeja B, Rundle A, Gurwitz J, Gore J, Barron H
Am J Cardiol
. 2001 Mar;
87(5):627-30, A9.
PMID: 11230850
In a retrospective cohort of patients treated in community hospitals, tissue plasminogen activator (t-PA) was associated with decreased odds of in-hospital death or nonfatal stroke. However, the relative benefit was...